Jing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jing Liu has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Salim Shahbuddin Virani
Aga Khan University
4 shared publications - Christie M. Ballantyne
Department of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.).
2 shared publications - Dhruv Mahtta
Section of Cardiology Department of Medicine, Baylor College of Medicine, Houston, USA
2 shared publications - Mahmoud Al Rifai
Section of Cardiology Department of Medicine, Baylor College of Medicine, Houston, USA
2 shared publications - Vardhmaan Jain
Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, USA
2 shared publications - Abdulla Al Damluji
Cardiovascular Center on Aging, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio, USA
1 shared publication
Latest Publications
- Open Access
- 17 December 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102330
Gender Matters
- 17 December 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (12) , 102330
Open AccessGender Matters
- 6 July 2021
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (9) , 1-10
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention
Purpose of Review This review highlights late-breaking science presented at the Virtual American College of Cardiology Scientific Sessions 2021 that demonstrated advancements in preventative cardiology and introduced novel therapeutic modalities for the management of chronic kidney disease, heart failure, and COVID-19. Recent Findings The studies reviewed include clinical trials that assessed the use of dapagliflozin in patients with respiratory failure due to COVID-19 (DARE-19 trial); evinacumab for patients with severe hypertriglyceridemia and pancreatitis; effect of genotype-guided oral P2y12 inhibitors vs conventional clopidogrel on long-term ischemic outcomes after percutaneous coronary intervention (TAILOR-PCI trial); anticoagulation in patients hospitalized with COVID-19 (ACTION trial); atorvastatin vs placebo in patients with COVID-19 admitted to the ICU (INSPIRATION-S trial); rehabilitation therapy in older acute heart failure patients (REHAB-HF trial); and aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE trial). In addition, we review the results of the American College of Cardiology Global Heart Attack Initiative (GHATI). Finally, we discuss the secondary analysis of the STRENGTH trial assessing the association of achieved levels of omega-3 fatty acid levels and major cardiovascular outcomes. Summary The studies presented at the virtual American College of Cardiology Scientific Session 2021 represent remarkable contributions in the field of cardiovascular disease and prevention.
- 6 July 2021
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (9) , 1-10
Highlights from Studies Presented at the Virtual American College of Cardiology Scientific Sessions 2021: Staying Updated with the Latest Advancements in Prevention
Purpose of Review This review highlights late-breaking science presented at the Virtual American College of Cardiology Scientific Sessions 2021 that demonstrated advancements in preventative cardiology and introduced novel therapeutic modalities for the management of chronic kidney disease, heart failure, and COVID-19. Recent Findings The studies reviewed include clinical trials that assessed the use of dapagliflozin in patients with respiratory failure due to COVID-19 (DARE-19 trial); evinacumab for patients with severe hypertriglyceridemia and pancreatitis; effect of genotype-guided oral P2y12 inhibitors vs conventional clopidogrel on long-term ischemic outcomes after percutaneous coronary intervention (TAILOR-PCI trial); anticoagulation in patients hospitalized with COVID-19 (ACTION trial); atorvastatin vs placebo in patients with COVID-19 admitted to the ICU (INSPIRATION-S trial); rehabilitation therapy in older acute heart failure patients (REHAB-HF trial); and aspirin dosing: a patient-centric trial assessing benefits and long-term effectiveness (ADAPTABLE trial). In addition, we review the results of the American College of Cardiology Global Heart Attack Initiative (GHATI). Finally, we discuss the secondary analysis of the STRENGTH trial assessing the association of achieved levels of omega-3 fatty acid levels and major cardiovascular outcomes. Summary The studies presented at the virtual American College of Cardiology Scientific Session 2021 represent remarkable contributions in the field of cardiovascular disease and prevention.
- 3 January 2021
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (1) , 1-9
Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention
Purpose of the Review This review highlights late-breaking science presented at the American Heart Association Scientific Session 2020 that demonstrated advancements in preventative cardiology and introduced novel treatment approaches for the management of chronic kidney disease, type 2 diabetes, and/or heart failure. Recent Findings The studies reviewed include clinical trials that assessed the use of omecamtiv in the treatment of heart failure with reduced heart failure (GALACTIC-HF); effects of sotagliflozin in patients with diabetes and recent heart failure exacerbation; cardiovascular outcomes with the use of omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH) and omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI); efficacy and safety of evinacumab in patients with refractory hypercholesterolemia; and the use of coronary computed tomography angiography for the assessment of suspected acute coronary syndrome. In addition, we review the results of the International Polycaps Study (TIPS-3) on the use of a polypill for the primary prevention of cardiovascular disease in intermediate-risk people. Finally, we discuss the SAMSON trial—a three-arm-N-of-1 trial—to identify the root cause of the symptoms contributing to patient nonadherence to statin therapy. Summary The studies presented at the American Heart Association Scientific Session 2020 represent remarkable contributions in the field of cardiovascular disease and prevention.
- 3 January 2021
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 23 (1) , 1-9
Highlights from Studies Presented at the American Heart Association Scientific Session 2020: Navigating New Roads in Prevention
Purpose of the Review This review highlights late-breaking science presented at the American Heart Association Scientific Session 2020 that demonstrated advancements in preventative cardiology and introduced novel treatment approaches for the management of chronic kidney disease, type 2 diabetes, and/or heart failure. Recent Findings The studies reviewed include clinical trials that assessed the use of omecamtiv in the treatment of heart failure with reduced heart failure (GALACTIC-HF); effects of sotagliflozin in patients with diabetes and recent heart failure exacerbation; cardiovascular outcomes with the use of omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia (STRENGTH) and omega-3 fatty acids in elderly patients with recent myocardial infarction (OMEMI); efficacy and safety of evinacumab in patients with refractory hypercholesterolemia; and the use of coronary computed tomography angiography for the assessment of suspected acute coronary syndrome. In addition, we review the results of the International Polycaps Study (TIPS-3) on the use of a polypill for the primary prevention of cardiovascular disease in intermediate-risk people. Finally, we discuss the SAMSON trial—a three-arm-N-of-1 trial—to identify the root cause of the symptoms contributing to patient nonadherence to statin therapy. Summary The studies presented at the American Heart Association Scientific Session 2020 represent remarkable contributions in the field of cardiovascular disease and prevention.
- 1 November 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (11) , 1293-1301.e1
Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction
- 1 November 2020
- Published by Elsevier in The American Journal of Medicine
- Vol. 133 (11) , 1293-1301.e1
Age-Stratified Sex Disparities in Care and Outcomes in Patients With ST-Elevation Myocardial Infarction
- 21 November 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (12) , 53
Role of Coronary Calcium Score to Identify Candidates for ASCVD Prevention
In this review, we describe the mechanism behind coronary artery calcification formation and detection, as well as its implication in cardiovascular disease (CVD) risk stratification, intervention, and prognosis in asymptomatic individuals.
- 21 November 2019
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 21 (12) , 53
Role of Coronary Calcium Score to Identify Candidates for ASCVD Prevention
In this review, we describe the mechanism behind coronary artery calcification formation and detection, as well as its implication in cardiovascular disease (CVD) risk stratification, intervention, and prognosis in asymptomatic individuals.
- Open Access
- 1 November 2019
- Published by Elsevier in Indian Heart Journal
- Vol. 71 (6) , 434-439
QT prolongation in HIV-positive patients: Review article
- 1 November 2019
- Published by Elsevier in Indian Heart Journal
- Vol. 71 (6) , 434-439
Open AccessQT prolongation in HIV-positive patients: Review article
- 1 November 2019
- Published by Elsevier in Journal of Electrocardiology
- Vol. 57, 128-131
ST segment elevation following coronary artery bypass surgery
- 1 November 2019
- Published by Elsevier in Journal of Electrocardiology
- Vol. 57, 128-131
ST segment elevation following coronary artery bypass surgery
- 23 May 2019
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 13 (7) , 1-8
The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines
Purpose of Review In 2018, the AHA/ACC Multi-Society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk-enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment. Recent Findings The risk-enhancing factors are high-risk features that may guide the use of lipid-lowering therapy particularly in intermediate and select borderline-risk patients. For the purpose of this review, these factors are divided into five categories: (i) race and genetics, (ii) conditions specific to women, (iii) lipid-related risk, (iv) concurrent high-risk medical conditions, and (v) biomarkers. Summary The addition of the risk-enhancing factors to the pooled cohort equations provides a more individualized and comprehensive approach to cardiovascular disease risk assessment.
- 23 May 2019
- Published by Springer Nature in Current Cardiovascular Risk Reports
- Vol. 13 (7) , 1-8
The Use of Risk-Enhancing Factors to Personalize ASCVD Risk Assessment: Evidence and Recommendations from the 2018 AHA/ACC Multi-Society Cholesterol Guidelines
Purpose of Review In 2018, the AHA/ACC Multi-Society Cholesterol Guidelines introduced the novel concept of risk-enhancing factors to be used as a supplement to the pooled cohort risk equations to personalize atherosclerotic cardiovascular disease risk assessment in primary prevention. In this review, we discuss the rationale and evidence behind each of the risk-enhancing factors to help clinicians perform a more personalized cardiovascular risk assessment. Recent Findings The risk-enhancing factors are high-risk features that may guide the use of lipid-lowering therapy particularly in intermediate and select borderline-risk patients. For the purpose of this review, these factors are divided into five categories: (i) race and genetics, (ii) conditions specific to women, (iii) lipid-related risk, (iv) concurrent high-risk medical conditions, and (v) biomarkers. Summary The addition of the risk-enhancing factors to the pooled cohort equations provides a more individualized and comprehensive approach to cardiovascular disease risk assessment.
- 10 October 2016
- Published by Springer Nature in Current Tropical Medicine Reports
- Vol. 3 (4) , 181-183
Brucellosis Prostatitis: A Neglected Diagnosis for a Tropical Disease
- 10 October 2016
- Published by Springer Nature in Current Tropical Medicine Reports
- Vol. 3 (4) , 181-183
Brucellosis Prostatitis: A Neglected Diagnosis for a Tropical Disease